OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to…
AI Summary & Key Takeaways
- OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind
- The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems
- Developing a new drug in the US takes ten to…
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
Related stories
Paragon: weekly digest
Paragon: weekly digest Our analyzes and materials: 🟠5 reasons that prevent you from making money with AI 🟠ElevenLabs: what is available for free, except for voice acting 🟠$300 for a YouTube cover: start plan in 5 days 🟠Poe: collecting your own AI from Claude, GPT and Gemini 🟠11 AI services where...
The hottest AI wearables and gadgets you should know about
We compiled a list of all the hottest AI wearables, including Muse Charm, Bee, Friend, Plaud, and more.
Walmart will allow AI agents to make purchases on their own while Amazon blocks them
Walmart will allow AI agents to make purchases on their own while Amazon blocks them The American retail chain Walmart has introduced Agent Gateway, a new system that will allow AI agents to select products and make purchases on behalf of users. Unlike the competitor...
AI news digest for October 25, 2026
Today we're highlighting a new language model from Moonshot that promises to be a leader in open source solutions, and a surprising innovation from Pennsylvania where AI-generated advertising should be